Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00677859 · ClinicalTrials.gov registry record · Phase 1

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

A Phase 1 study of Hematologic Malignancies, sponsored by Healios K.K..

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
6
Study locations

NCT00677859: Completed Phase 1 study of Hematologic Malignancies, sponsored by Healios K.K..

NCT00677859 is a Phase 1 study of Hematologic Malignancies that has completed, run by Healios K.K.. The registered enrollment target is 36 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00677859, a Phase 1 study of Hematologic Malignancies, has completed, sponsored by Healios K.K..

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.

Conditions Studied

Hematologic Malignancies

Interventions

  • BIOLOGICAL MultiStem®

Study Locations (6)

Arizona

  • Mayo Clinic Hospital - Phoenix

Ohio

  • University Hospitals Case Medical Center - Cleveland

Oregon

  • Oregon State University Medical Center - Portland

Pennsylvania

  • University of Pennsylvania - Philadelphia

Texas

  • Texas Transplant Institute - San Antonio

Other

  • UZ Leuven - Leuven

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2008-07
Est. Completion 2011-11
Phase Phase 1
Healios K.K.

6 total trials

What the finished NCT00677859 record still lists

NCT00677859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MultiStem® is the first listed.

NCT00677859 lists 6 locations in 6 states (Arizona, Ohio, Oregon).

Frequently Asked Questions

What is clinical trial NCT00677859 about?

NCT00677859 is a clinical study titled "Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia". The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.

What is the current status of trial NCT00677859?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-07. Estimated completion is 2011-11.

What conditions does trial NCT00677859 study?

This clinical trial studies the following conditions: Hematologic Malignancies.

What interventions are being tested in trial NCT00677859?

The interventions under investigation include: MultiStem® (BIOLOGICAL).

Who is sponsoring clinical trial NCT00677859?

This trial is sponsored by Healios K.K., which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00677859 being conducted?

This trial has 6 study locations across Arizona, Ohio, Oregon, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hematologic Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00677859's enrollment target sits among peer trials

36 32nd of 45 higher than 14 of 45 other Hematologic Malignancies trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00677859, the US trial registry maintained by the National Library of Medicine. NCT00677859 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.